2024
Salcher-Konrad M, Nguyen M, Savović J, Higgins JPT, Naci H. Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis. JAMA Netw Open. 2024;7(9):e2436230. doi:10.1001/jamanetworkopen.2024.36230
Vogler S, Steigenberger C, Windisch F. Improving antibiotic prescribing - Recommendations for funding and pricing to enhance use of point-of-care tests. Health Policy OPEN. 2024, doi.org/10.1016/j.hpopen.2024.100129
Vogler S, Habimana K, Haasis MA, Fischer S. Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally. Applied Health Economics and Health Policy. 2024. doi.org/10.1007/s40258-024-00888-y
Vogler S, Zimmermann N, Haasis MA, Knoll V, Espin J, Mantel-Teeuwisse AK, et al. Innovations in pharmaceutical policies and learnings for sustainable access to affordable medicines. Journal of Pharmaceutical Policy and Practice. 2024;17(sup1): 2335492
Vogler S. Tackling medicine shortages during and after the COVID-19 pandemic. Compilation of governmental policy measures and developments in 38 countries. Health Policy. 2024(143): 105030.
2023
Leopold C, Poblete S, Vogler S. How to Price and to Reimburse Publicly Funded Medicines in Latin America? Lessons Learned from Europe. Journal of Law, Medicine & Ethics. 2023;51(S1): 76-91. Epub 2023/12/29.
Steigenberger C, Windisch F, Vogler S. Barriers and Facilitators in Pricing and Funding Policies of European Countries That Impact the Use of Point-of-Care Diagnostics for Acute Respiratory Tract Infections in Outpatient Practices. Diagnostics. 2023;13, 3596. https://doi.org/10.3390/diagnostics13233596
Vogler S, Salcher-Konrad M, Habimana K. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines? Expert Review of Pharmacoeconomics & Outcomes Research. 2023;23(8):867-878
Rodríguez Sánchez DI, Vogler S. Shortages of Medicines to Treat COVID-19 Symptoms during the First Wave and Fourth Wave: Analysis of Notifications Reported to Registers in Austria, Italy, and Spain. Pharmacy. 2023;11(4):120.
Ivama-Brummell AM, Marciniuk FL, Wagner AK, Osorio-de-Castro CGS, Vogler S, Mossialos E, Tavares-de-Andrade CL, Naci H. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis. The Lancet Regional Health – Americas. 2023;22
Davis C, Wagner AK, Salcher-Konrad M, Scowcroft H, Mintzes B, Pokorny AMJ, Lew J, Naci H. Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ. 2023;380:e073711. doi:10.1136/bmj-2022-073711
Årdal C, Baraldi E, Busse R, Castro R, Ciabuschi F, Cisneros JM, Gyssens IC, Harbarth S, Kostyanev T, Lacotte Y, Magrini N, McDonnell A, Moon S, Peñalva G, Ploy MC, Radulović M, Ruiz AA. Røttingen JA, Sharland M, Tacconelli E, Theuretzbacher U, Vogler S, Sönksen UW, Åkerfeldt K, Cars O, O'Neill J. Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation. The Lancet 2023. doi.org/10.1016/S0140-6736(23)00282-9
Perelman J, Duarte-Ramos F, Melo Gouveia A, Pinheiro L, Ramos F, Vogler S, Mateus, C. How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021. Expert Review of Pharmacoeconomics & Outcomes Research. 2023;23(1):99-109
2022
Vogler S: Prices of new medicines: International analysis and policy options. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2022
Vogler S, Windisch F: Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections - Overview of Policies Applied in 17 European Countries. Antibiotics. 2022:11(8):987
Vogler S, Zimmermann N: Improving medicines access in Brazil through collaboration in the PPRI network. Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde. 2022; 13(2): 677
Cherla A, Mossialos E, Salcher-Konrad M, Kesselheim AS, Naci H: Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. Clinical Pharmacology and Therapeutics. 2022. doi:10.1002/cpt.2679
Vogler S, Bauer E, Habimana K: Centralised Pharmaceutical Procurement: Learnings from Six European Countries. Applied Health Economics and Health Policy. 2022(20): 637-650
Vogler S: Pharmaceutical regulation and policies in Austria. Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde. 2022; 13(1): 639
Vogler S: “Ready for the future?”–Status of national and cross-country horizon scanning systems for medicines in European countries. GMS German Medical Science — an Interdisciplinary Journal. 2022;22
Vogler S, Habimana K, Haasis MA: Purchasing medicines for the public sector: Evaluation of the performance of centralised procurement in Portugal. The International Journal of Health Planning and Management 2022:37:2007-31
Moye-Holz D, Vogler S. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America. Applied Health Economics and Health Policy 2022(20): 67-77
2021
Vogler S, Haasis MA, van den Ham R, Humbert T, Garner S, Suleman F. European collaborations on medicine and vaccine procurement. Bulletin of the World Health Organization 2021, 99(10):715-721
Jommi C, Addis A, Martini N, Nicod E, Pani M, Scopinaro A, Vogler S. Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework? Global & Regional Health Technology Assessment. 2021;8: 114-9.
Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. Frontiers in Pharmacology 2021, https://doi.org/10.3389/fphar.2021.625296
Russo P, Carletto A, Németh G, Habl C. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. Health Policy 2021; 125(9): 1140-1145
Vogler S.: Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Review of Pharmacoeconomics & Outcomes Research. 2021: 1-5
Vogler S, Zimmermann N, Babar-Ud-Din Z, Busse R, Espin Balbino J, et al.: Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. Journal of Pharmaceutical Policy and Practice 2021; 14(18)
2020
Vogler S, Schneider P, Lepuschütz L.: Impact of changes in the methodology of external price referencing on medicine prices:discrete-event simulation. Cost Effectiveness and Resource Allocation 2020; 18(51)
Gombocz M, Vogler S.: Public spending on orphan medicines: a review of the literature. Journal of Pharmaceutical Policy and Practice 2020; 13 (66)
Vogler S, Fischer S.: How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Health Policy 2020; 124(12): 1287-1296
Gamba S, Pertile P, Vogler S.: The impact of managed entry agreements on pharmaceutical prices. Health Economics 2020; 29 (S1): 47-62
Rintoul A, Colbert A, Garner S, Kotwani A, Vogler S, Bouvy J et al.: Medicines with one seller and many buyers: strategies to increase the power of the payer. BMJ 2020; 369: m1705
Ferrario A, Dedet G, Humbert T, Vogler S, Suleman F, Bak Pedersen H.: Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ 2020; 368 :l5444
2019
Vogler S, Zimmermann N, Haasis MA, Babar-Ud-Din Z, Busse R, Espin Balbino J, et al.: Can pharmaceutical pricing and reimbursement policies make a difference in promoting equitable access to affordable medicines? From diagnosis to sustainable impact. Editorial. 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies: Vienna, Austria. 23-24 October 2019. Journal of Pharmaceutical Policy and Practice. 2019;12(Suppl 1):34
Vogler S.: Il miglioramento dei processi, la cooperazione, l’evidenza e la trasparenza: i temi chiave per le proposte di riforma delle politiche sul prezzo e rimborso dei farmaci. (Title in English: Improvement of processes, cooperation, evidence and transparency: the key proposals for reforming pharmaceutical pricing and reimbursement policies) Politiche sanitarie 2019; 20(4):180-182
Vogler S, Dedet G, Bak Pedersen H.: Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries. Appl Health Econ Health Policy 17 2019; 803–816; doi:10.1007/s40258-019-00509-z
Vogler S, Schneider P, Dedet G, Bak Pedersen H. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan. International Journal for Equity in Health. 2019;18(1):89
Vogler S.: Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies. Empirica - Journal of European Economics 2019; 46(3), 443-469
Vogler S, Schneider P.: Assessing Data Sources for Medicine Price Studies. International Journal of Technology Assessment in Health Care 2019; 35(2): 106-115
Vogler S, Schneider P, Zimmermann N.: Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. PharmacoEconomics - Open (2019) 3:303–309
Mardetko N, Kos M, Vogler S.: Review of studies reporting actual prices for medicines. Expert review of pharmacoeconomics & outcomes research 2019; 19(2): 159-179
2018
Vogler S, de Rooij R.: Medication wasted – Contents and costs of medicines ending up in household garbage. Research in Social and Administrative Pharmacy, 2018, Volume 14, Issue 12, December 2018, Pages 1140-1146
2017
Gammie T, Vogler S, Babar Z-U-D.: Economic Evaluation of Hospital and Community Pharmacy Services: A Review of the Literature (2010-2015). Annals of Pharmacotherapy, 51(1): 54-65, 2017
Schneider P, Renner A, Bobek J, Vogler S, Ostermann H.: Economic Evaluation of Minor Ailment Schemes (MAS). DOI: 10.1055/s-0042-120488, Gesundheitsökonomie & Qualitätsmanagement, 2017, 22(S 01): S23-S29
Morgan S, Vogler S, Wagner A.: Payers’ experiences with confidential pharmaceutical Price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy, 121, Issue 4: 354-362, April 2017, http://dx.doi.org/10.1016/j.healthpol.2017.02.002
Pauwels K, Huys I, Vogler S, Casteels M, Simoens S.: Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Frontiers in Pharmacology, 2017, doi: 10.3389/fphar.2017.00171
Schneider P, Vogler S, Zimmermann N.: Oberes Mittelfeld - Ergebnisse einer Preisvergleichsstudie zu kostenintensiven Arzneimitteln. (Title in English: Upper midrange - anaylsis of high priced medicines in Austria), Das österreichische Gesundheitswesen – ÖKZ, 58. Jg. (2017), 05: 15-17, 2017
Vogler S, Paterson K.: Can Price Transparency Contribute to More Affordable Patient Access to Medicines?. PharmacoEconomics Open, 1 (3): 145-147, 2017
Vogler S, Gombocz M, Zimmermann N.: Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands. Journal of Pharmaceutical Health Services Research, 2017, Volume 8, Issue 3, September 2017, Pages 147-158
Vogler S, Schneider P.: Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey. Generics and Biosimilars Initiative Journal (GaBI Journal), 6(2): 79-88, 2017
Vogler S, Paris V, Ferrario A, Wirtz V, de Joncheere K, Schneider P.: How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Applied Health Economics and Health Policy, 15: 307-321, 2017
Vogler S, Zimmermann N, Babar Z-U-D: Price comparison of high-cost originator medicines in European countries. Expert Review of Pharmacoeconomics & Outcomes 17 (2): 221-230
2016
Vogler S, Babar Z-U-D, Vitry A.: Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. The Lancet Oncology 17(1), No. 1: 39-47, 2016
Vogler S, Zimmermann N, Ferrario A, Wirtz V, de Joncheere K, Bak Pedersen H, Dedet G, Paris V, Mantel-Teeuwisse A, Babar Z-U-D and on behalf of the Scientific Programme Committee: Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Journal of Pharmaceutical Policy and Practice, 9: 9, 2016
Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, De Joncheere K, Hill S. : Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med, 13: 5, 2016
Pani L, Montilla S, Németh G, Russo P, Viceconte G, Vogler S.: Balancing Access to Medicines and Sustainability in Europe: an Analysis from the Network of Competent Authorities on Pricing and Reimbursement (CAPR). Pharmacological Research, S1043-6618(16)30202-X, 2016
Vogler S, Habimana K, Zimmermann N.: Stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement . Health Policy and Technology, 5; Issue 3: 213–225 , September 2016
Vogler S, Zimmermann N, de Joncheere K.: Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015. Health Policy, 120, Issue 12: 1363–1377, December 2016
2015
Vogler S, Kilpatrick K, Babar Z-U-D.: Analysis of Medicine Prices in New Zealand and 16 European Countries. Value in Health 2015, 18(4), 2015
Vogler S, Österle A, Mayer S.: Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. International Journal for Equity in Health, 14: 124, 2015
2014
Vogler S, Zimmermann N.: Aktivitäten von Krankenversicherungsträgern zur Etablierung eines rationalen Einsatzes von Arzneimitteln. Im Blickpunkt, 1/2014, 2014
Vogler S, Leopold C, Zimmermann N, Habl C, de Joncheere K.: The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative-Experiences from engaging with pharmaceutical policy makers. Health Policy and Technology 2014, 3: 139-148, 2014
Vogler S, Leopold C, Zuidberg C, Habl C.: Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna. Journal of Pharmaceutical Policy and Practice 2014, 7(1): 6, 2014
Vogler S, Habimana K, Arts D.: Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries. Health Policy 2014, 117(3): 311-327, 2014
Leopold C, Mantel-Teeuwisse A.K, Vogler S, Valkova S, de Joncheere K, Leufkens H.G.M, Wagner A, Ross-Degnan D, Laing R.: Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bulletin of the World Health Organization 2014 , 92:630-640D
Leopold C, Zhang F, Mantel-Teeuwisse A.K., Vogler S, Valkova S, Ross-Degnan D, Wagner A.K.: Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. International Journal for Equity in Health 2014 , 13:53
Babar Z-U-D, Gray A, Kiani A, Vogler S, Ballantyne P, Scahill S. : The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change. Journal of Pharmaceutical Policy and Practice 2014, 7(1): 1-2, 2014
Vogler S, Zimmermann N, Mazag J.: Availability and procurement conditions of originator and generic medicines in hospitals – an exploratory study in five medium-sized European countries. Generics and Biosimilars Initiative Journal (GaBI Journal) 2014, 3(4): 168-75, 2014
2013
Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J.: Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries. The Open Pharmacoeconomics & Health Economics Journal 2013, 5: 1-10, 2013
Vogler S, Zimmermann N, Habl C, Mazag J. : The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. Cost Effectiveness and Resource Allocation 2013, 11: 15, 2013
Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, Malmström R, Vogler S, Godman B, Gustafsson LL.: Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. European Journal of Clinical Pharmacology 2013, 69(1): 73-8, 2013
Leopold C, Mantel-Teeuwisse A.K, Vogler S, de Joncheere K, Laing R.O, Leufkens H.G.M.: Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 2013, 112: 209-16, 2013
Vogler S, Zimmermann N.: How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. Generics and Biosimilars Initiative Journal (GaBI Journal) 2013, 2(2): 65-75, 2013
Leopold C, Vogler S, Piessnegger J, Bucsics A.: Aktuelle Heilmittelausgaben und arzneimittelpolitische Trends in Europa. Soziale Sicherheit 2013, 9: 414-429, 2013
Leopold C, Vogler S, Habl C, Mantel-Teeuwisse A.K, Espin J.: Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab. Health Policy 2013, 113(3): 313–22, 2013
Vogler S, Zimmermann N, Habl C.: Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries. Generics and Biosimilars Initiative Journal (GaBI Journal) 2013, 2(4): 178-87, 2013
2012
Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A.: Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review 2012, 5(1): 38-46, 2012
Vogler S.: The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview. Generics and Biosimilars Initiative Journal (GaBI Journal) 2012, 1(2): 93-100, 2012
Vogler S.: Preisbildung und Erstattung von Arzneimitteln in der EU - Gemeinsamkeiten, Unterschiede und Trends. [Title translated in English: Pricing and reimbursement of medicines in the EU], Pharmazeutische Medizin 2012, 14: 48-56, 2012
Leopold C, Vogler S, Mantel-Teeuwisse A, de Joncheere K, Leufkens H.G.M, Laing R.: Differences in external price referencing in Europe - A descriptive overview. Health Policy 2012, 104: 1, 2012
Vogler S.: How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Farmeconomia: Health economics and therapeutic pathways 2012, 13 (Suppl 3): 29-41, 2012
Vogler S, Zimmermann N.: The potential of generics policies: more room for exploitation. PPRI Conference Report. Generics and Biosimilars Initiative Journal (GaBI Journal) 2012, 1(3-4): 146-9, 2012
Leopold C, Mantel-Teeuwisse A.K, Seyfang L, Vogler S, de Joncheere K, Laing R.O, Leufkens H.G.M.: Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries. Southern Med Review 2012, 5(2): 34-41, 2012
2011
Vogler S, Habl C, Bogut M, Voncina L.: Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croatian Medical Journal (CMJ) 2011, 52: 183-97, 2011
Vogler S, Zimmermann N, Mazag J.: Procuring medicines in hospitals: results of the European PHIS survey. European Journal of Hospital Pharmacy Practice 2011, 17: 20-21, 2011
Editors of Medical Tribune.: Weltweit ähnliche Probleme: Arzneien & Sparzwang. [Title translated in English: Worldwide similar problems: Medicines & the need for cost-savings], 2011
Vogler S, Zimmermann N, Leopold C, de Joncheere K.: Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review 2011, 4: 22-32, 2011
2010
Vogler S.: A European survey on medicines management in hospitals. European Journal of Hospital Pharmacy Practice 2010, 16: 12, 2010
2009
Vogler S, Espin J, Habl C.: Pharmaceutical Pricing and Reimbursement Information (PPRI) – new PPRI analysis including Spain. Pharmaceuticals Policy and Law 2009, 11: 213-34, 2009
2008
Vogler S.: Arzneimittelpreisbildung und Arzneimittelerstattung in der EU. [Title translated in English: Pharmaceutical pricing and reimbursement in the EU], Austrian Public Health Association Newsletter 2008, 4: 1-2, 2008
Leopold C, Vogler S, Habl C.: Was macht ein erfolgreiches Referenzpreissystem aus – Erfahrungen aus internationaler Sicht. [Title translated in English: Implementing a successful reference price system – Experiences from other countries], Soziale Sicherheit 2008, 11: 614-23, 2008
2006
Vogler S, Habl C, Leopold C.: Arzneimittel – wer zahlt? Erstattung und Selbstbeteiligung in der erweiterten EU. [Title translated in English: Pharmaceuticals: Who pays? Reimbursement and co-payments in the enlarged EU], Soziale Sicherheit 2006, 9: 411-8, 2006
Arts D, Habl C, Rosian I, Vogler S.: Pharmaceutical Pricing and Reimbursement Information (PPRI): a European Union project. Italian Journal of Public Health 2006, 3: 36-40, 2006
2003
Rosian I, Vogler S, Vander Stichele R, Larsen L, Odegaard B, Brahm A, et al.: EURO-MED-STAT–Monitoring expenditure and utilization of medicinal products in the European Union countries: a Public Health approach. European Journal of Public Health, 13 (3 Supplement): 95-100, 2003
2002
Rosian I, Vogler S.: Arzneimittelsysteme in Europa – ein vergleichender Überblick. [Title translated in English: Pharmaceutical systems in Europe – a comparative overview], Soziale Sicherheit 2002, 4: 165-74, 2002